1

Scancell

Scancell
Leadership team

Prof. Lindy Gillian Durrant Ph.D. (Founder, CEO, Chief Scientific Officer & Director)

Dr. Sally Elizabeth Adams (Chief Devel. Officer & Director)

Mr. Keith Green (Director of Fin. & Admin. and Company Sec.)

Products/ Services
Biotechnology, Health Care
Number of Employees
0 - 50
Headquarters
Nottingham, Nottingham, United Kingdom
Established
1996
Traded as
LSE:SCLP
Social Media
Overview
Location
Summary
Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, an ImmunoBody cancer vaccine for the treatment of metastatic melanoma; SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.
History

Scancell is a world-leading bio-medical company focused on the development of novel immunotherapies for the treatment of cancer and associated diseases. The company was founded in 2001 by Professor Lindy Durrant, who recognised the potential of novel monoclonal antibody-based therapies, and is now backed by a clinical research and development team of experienced thought-leaders from the drug development sector. Scancell has a strong track record of success in product development and clinical validation, having successfully delivered a range of innovative products for patients through seeking regulatory approval and global partnerships.

Mission
Scancell’s mission is to develop and delivery novel immunotherapies for the treatment of cancer and associated diseases. We are focused on identifying and developing products that have the potential to generate improved outcomes for patients and have chosen to build our business on achieving this goal.
Vision
Scancell is committed to revolutionising the treatment of cancer and other life-threatening diseases by providing innovative and targeted immunotherapies to improve patient outcomes. We are dedicated to transforming the lives of cancer patients and are focused on developing solutions that can reduce treatment toxicity and maximise therapeutic benefit.
Key Team

Dr. Samantha Paston Ph.D. (Head of Translational Research)

Dr. Adrian Parry Ph.D. (Head of Manufacturing)

Ms. Akua Asare (Head of Quality)

Mr. Fayaz Master (Head of Clinical Operations)

Recognition and Awards
Scancell has received a number of awards and accolades in recognition of our achievements in the fields of medical innovation and healthcare. These include awards from the London Stock Exchange Group , the International Society of Oncology Pharmacists , and the Royal Academy of Engineering , among others.
References

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Scancell
Leadership team

Prof. Lindy Gillian Durrant Ph.D. (Founder, CEO, Chief Scientific Officer & Director)

Dr. Sally Elizabeth Adams (Chief Devel. Officer & Director)

Mr. Keith Green (Director of Fin. & Admin. and Company Sec.)

Products/ Services
Biotechnology, Health Care
Number of Employees
0 - 50
Headquarters
Nottingham, Nottingham, United Kingdom
Established
1996
Traded as
LSE:SCLP
Social Media